Guardant Health, Inc. (NASDAQ:GH) Director Sells $86,590.40 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Guardant Health Stock Performance

GH opened at $29.11 on Friday. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $37.04. The business’s 50-day simple moving average is $23.68 and its 200-day simple moving average is $26.47.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company had revenue of $191.48 million during the quarter, compared to analysts’ expectations of $170.49 million. During the same quarter in the prior year, the company earned ($0.73) earnings per share. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. As a group, analysts forecast that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Institutional Investors Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently bought and sold shares of GH. Swiss National Bank increased its position in Guardant Health by 3.3% during the first quarter. Swiss National Bank now owns 227,700 shares of the company’s stock worth $4,697,000 after buying an additional 7,300 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of Guardant Health by 254.0% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 114,125 shares of the company’s stock valued at $2,354,000 after acquiring an additional 81,887 shares during the period. First Light Asset Management LLC raised its position in Guardant Health by 119.7% in the 2nd quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock valued at $12,042,000 after purchasing an additional 227,202 shares during the last quarter. International Assets Investment Management LLC raised its position in Guardant Health by 2,193.9% in the 3rd quarter. International Assets Investment Management LLC now owns 10,208 shares of the company’s stock valued at $2,340,000 after purchasing an additional 9,763 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in Guardant Health during the 2nd quarter worth $831,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. TD Cowen increased their price target on shares of Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. UBS Group increased their target price on shares of Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. Leerink Partners decreased their price target on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. The Goldman Sachs Group upped their price objective on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their target price on Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.